An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

Roche

Status: Completed

Conditions: Hepatitis C, Chronic

Study type: Observational

Funder types: Industry

Identifiers

NCT01679834

ML25724

Details and patient eligibility

About

This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.

Enrollment: 7,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Diagnosis of chronic hepatitis C
• Patients receiving treatment with Pegasys and/or Copegus (ribavirin) and/or a protease inhibitor according to local label

Exclusion criteria

• Contraindications against Pegasys or Copegus
• Not willing or unable to sign written informed consent form

Trial design

7,500 participants in 1 patient group

Cohort